It really is a new Endo Health (ENDP).
I've gone on at length about how past management did their best to try to ruin a once-strong specialty pharmaceutical business, but the announcement of a deal to acquire Paladin Labs (PLDLF) is a true transformational deal in all of the right ways. Endo still has challenges to deal with, including generic competition for two major products and surgical mesh litigation, but the company seems to be handling the generic issue pretty well and the acquisition of Paladin will significantly expand the company's specialty pharma business and generate substantial tax savings by redomiciling in Ireland.
The only "but" is valuation. While I do believe that Endo Health's guidance...
Only subscribers can access this article, which is part of the PRO research library covering 3,770 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: